Strs Ohio Decreases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Strs Ohio decreased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 5.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,300 shares of the biopharmaceutical company’s stock after selling 1,600 shares during the quarter. Strs Ohio’s holdings in Intra-Cellular Therapies were worth $1,883,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of ITCI. Phocas Financial Corp. bought a new stake in Intra-Cellular Therapies in the fourth quarter worth $1,949,000. Cerity Partners LLC purchased a new position in shares of Intra-Cellular Therapies in the fourth quarter worth about $266,000. DekaBank Deutsche Girozentrale lifted its stake in shares of Intra-Cellular Therapies by 26.8% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 51,997 shares of the biopharmaceutical company’s stock valued at $3,791,000 after acquiring an additional 11,000 shares during the last quarter. Prime Capital Investment Advisors LLC boosted its holdings in Intra-Cellular Therapies by 42.7% during the 4th quarter. Prime Capital Investment Advisors LLC now owns 9,168 shares of the biopharmaceutical company’s stock valued at $657,000 after acquiring an additional 2,743 shares during the period. Finally, International Assets Investment Management LLC bought a new position in Intra-Cellular Therapies during the 4th quarter worth approximately $51,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Trading Up 0.5 %

Shares of NASDAQ:ITCI opened at $72.37 on Friday. The stock has a fifty day simple moving average of $69.31 and a two-hundred day simple moving average of $64.10. Intra-Cellular Therapies, Inc. has a 12-month low of $45.50 and a 12-month high of $84.89. The stock has a market capitalization of $7.01 billion, a price-to-earnings ratio of -49.57 and a beta of 1.02.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.14. The firm had revenue of $132.10 million during the quarter, compared to the consensus estimate of $135.97 million. Intra-Cellular Therapies had a negative return on equity of 23.02% and a negative net margin of 30.08%. The company’s revenue was up 50.3% on a year-over-year basis. During the same period last year, the company earned ($0.45) earnings per share. As a group, equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.69 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Sharon Mates sold 20,565 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the sale, the chief executive officer now owns 1,050,309 shares in the company, valued at $68,490,649.89. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Sharon Mates sold 20,565 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $65.21, for a total value of $1,341,043.65. Following the completion of the transaction, the chief executive officer now owns 1,050,309 shares in the company, valued at $68,490,649.89. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Lawrence J. Hineline sold 13,337 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $69.43, for a total value of $925,987.91. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 168,487 shares of company stock valued at $11,364,950. Insiders own 3.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $82.00 price objective on shares of Intra-Cellular Therapies in a research report on Tuesday, April 16th. Mizuho lifted their target price on shares of Intra-Cellular Therapies from $76.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. Canaccord Genuity Group dropped their price target on shares of Intra-Cellular Therapies from $101.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, February 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $86.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, April 3rd. Finally, Bank of America upped their price objective on shares of Intra-Cellular Therapies from $82.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $86.17.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.